remifentanyl actavis 5 mg proszek do sporządzania koncentratu roztworu do wstrzykiwań lub infuzji
actavis group ptc ehf. - remifentanili hydrochloridum - proszek do sporządzania koncentratu roztworu do wstrzykiwań lub infuzji - 5 mg
pentasa 1 g tabletki o przedłużonym uwalnianiu
ferring gmbh - mesalazinum - tabletki o przedłużonym uwalnianiu - 1 g
pentasa 4 g granulat o przedłużonym uwalnianiu
ferring gmbh - mesalazinum - granulat o przedłużonym uwalnianiu - 4 g
pentasa 2 g granulat o przedłużonym uwalnianiu
ferring gmbh - mesalazinum - granulat o przedłużonym uwalnianiu - 2 g
ribavirin aurovitas 200 mg tabletki powlekane
aurovitas pharma polska sp. z o.o. - ribavirinum - tabletki powlekane - 200 mg
biocontrol t34
biocontrol technologies, s.l. avgda. madrid, 08014 barcelona, hiszpania - trichoderma asperellum szczep t34 - trichoderma asperellum szczep t34 - 120 g - fungicyd
rxulti
otsuka pharmaceutical netherlands b.v. - brexpiprazole - schizofrenia - psycholeptyki - leczenie schizofrenii.
sibnayal
advicenne s.a. - potassium citrate monohydrated, potassium hydrogen carbonate - acidosis, renal tubular - mineral supplements - sibnayal is indicated for the treatment of distal renal tubular acidosis (drta) in adults, adolescents and children aged one year and older.
plerixafor accord
accord healthcare s.l.u. - plerixafor - multiple myeloma; hematopoietic stem cell transplantation - Иммуностимуляторы, - adult patientsplerixafor accord is indicated in combination with granulocyte-colony stimulating factor (g-csf) to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in adult patients with lymphoma or multiple myeloma whose cells mobilise poorly (see section 4. paediatric patients (1 to less than 18 years)plerixafor accord is indicated in combination with g-csf to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in children with lymphoma or solid malignant tumours, either:- pre-emptively, when circulating stem cell count on the predicted day of collection after adequate mobilization with g-csf (with or without chemotherapy) is expected to be insufficient with regards to desired hematopoietic stem cells yield, or- who previously failed to collect sufficient haematopoietic stem cells (see section 4.